MedPath

EQMI-trial: Endoscopische Quad-Modal Imaging en moleculaire eindpunten ter opsporing van vroege neoplasie in Barrett oesophagus.

Conditions
Barrett oesophagus, refluxoesophagitis, Barrett oesophagitis, oesophaguscarcinoom, intestinal metaplasia, high grade dysplasia
Registration Number
NL-OMON21510
Lead Sponsor
To be determined
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
60
Inclusion Criteria

1. Age >18 yrs;

2. Circumferential BE >2 cm;

Exclusion Criteria

1. Prior surgical or endoscopic treatment of esophageal neoplasia;

2. Erosive esophagitis (> LA grade B);

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ENDPOINTS REAL-TIME IMAGING:<br /> <br>1. Correlation of real-time NBI vs. pCLE with histology; <br /><br>2. Reduction of the false-positive rate of WLE+AFI with NBI vs. pCLE;<br /><br><br /><br>ENDPOINTS MOLECULAR ANALYSIS: <br /><br>1. Correlation of AFI directed biopsies and yield of molecular abnormalities compared to random biopsies; <br /><br>2. Correlation of AFI patterns and molecular abnormalities in BE; <br /><br>3. Show that AFI increases detection of molecular markers with greater sensitivity and specificity than EQMI detection of dysplasia.<br>
Secondary Outcome Measures
NameTimeMethod
ENDPOINTS VIDEO/STILL IMAGE EVALUATION: <br /><br>1. Sensitivity and specificity for AFI-NBI vs. AFI-pCLE; <br /><br>2. Accuracy of predicting presence/absence of HGD/EC with NBI vs. pCLE in a blinded manner; <br /><br>3. Reduction of AFI FP lesions with NBI vs. pCLE; <br /><br>4. Inter-observer variability in classifying lesions with NBI vs. pCLE, using kappa statistics.
© Copyright 2025. All Rights Reserved by MedPath